May 5th, 2020 | 08:33 CEST
Evotec, Medigene, Memphasys - the right investment timing
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Society in change
Memphasys from Australia has focused on the topic of artificial insemination for several years. The market is growing because more and more couples are putting their professional career first and want to create an economic framework before completing the overall picture of a family with offspring.
However, the probability of a successful pregnancy decreases for both men and women with increasing age. Therefore, more and more couples consult medical experts to have fertilization monitored.
Market launch already in 2020
The Memphasys approach is based on the biological separation of high-quality sperm from the man's seminal fluid in order to subsequently increase the chances of success of artificial insemination. The device called FELIX carries out the separation in a few minutes, which means that the overall effort of the treatment is reduced and comfort is increased.
The product is to be launched in various countries as early as the second half of 2020. The company's market capitalisation on its home stock exchange in Australia was most recently AUD 45.34 million at AUD 0.06. The shares of Memphasys are also traded in Frankfurt.
In search of antibodies
The share price of Evotec, based in Hamburg, has been able to recover in recent weeks and was last traded at the same level as before the spread of COVID-19. Before the corona pandemic, the share price peaked at over EUR 26.00 and then dropped to a low of below EUR 19.00.
At the current level of EUR 22.30, Evotec is valued at EUR 3.36 billion. The company is engaged in the search for corona antibodies and in this context, there is a chance for investors to profit from the current situation.
Waiting for the breakthrough
Investors are currently having little luck with the shares of Medigene from Martinsried, near Munich. In the past 12 months, the share price has more than halved from over EUR 8.80 to EUR 4.16. Following the outbreak of the corona pandemic, the value of the shares even dropped to below EUR 3.40.
The market capitalisation of Medigene currently totals EUR 106.33 million. The successful development of immune therapies for the treatment of cancer will remain the company's value driver in the future. Patience is required.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.